Neurocrine Biosciences, Inc. [NBIX] stock is trading at $138.09, down -0.61%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NBIX shares have gain 0.36% over the last week, with a monthly amount drifted -0.38%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 10, April 2024, Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results. In a post published today on Yahoo Finance, Conference Call and Webcast Scheduled for Wednesday, May 1.
From an analyst’s perspective:
Previously, Deutsche Bank started tracking the stock with Buy rating on December 12, 2023, and set its price target to $136. Mizuho reiterated its Neutral rating and increased its price target to $113 on August 21, 2023. SVB Securities upgraded its rating to a Outperform and raised its price target to $125 on July 24, 2023. BMO Capital Markets upgraded its rating to Market Perform for this stock on July 06, 2023, and upped its price target to $96. In a note dated May 04, 2023, Guggenheim upgraded an Buy rating on this stock but restated the target price of $145.
Neurocrine Biosciences, Inc. [NBIX] stock has fluctuated between $89.04 and $148.37 over the past year. Currently, Wall Street analysts expect the stock to reach $126.75 within the next 12 months. Neurocrine Biosciences, Inc. [NASDAQ: NBIX] shares were valued at $138.09 at the most recent close of the market. An investor can expect a potential drop of -8.21% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Neurocrine Biosciences, Inc. [NASDAQ:NBIX] reported sales of 1.89B for the trailing twelve months, which represents a growth of 25.05%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.13 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 136.61 points at the first support level, and at 135.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 140.05, and for the 2nd resistance point, it is at 142.02.
Neurocrine Biosciences, Inc. [NBIX] reported earnings per share of $1.44 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.14/share, meaning a difference of $0.3 and a surprise factor of 26.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.82 per share as compared to estimates of $0.97 per share, a difference of -$0.15 representing a surprise of -15.50%.
Ratios To Look Out For
For context, Neurocrine Biosciences, Inc.’s Current Ratio is 2.45. In addition, the Quick Ratio stands at 2.40 and the Cash Ratio stands at 0.38. Considering the valuation of this stock, the price to sales ratio is 7.28, the price to book ratio is 6.11 and price to earnings (TTM) ratio is 56.83.
Transactions by insiders
Recent insider trading involved Delaet Ingrid, Chief Regulatory Officer, that happened on Apr 01 ’24 when 272.0 shares were sold. Chief Regulatory Officer, Delaet Ingrid completed a deal on Mar 21 ’24 to sell 5000.0 shares. Meanwhile, Chief Commercial Officer BENEVICH ERIC sold 75000.0 shares on Mar 14 ’24.
